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The influence of resident gut microbes on xenobiotic metabolism has been investigated at different levels
throughout the past five decades. However, with the advance in sequencing and pyrotagging technologies,
addressing the influence of microbes on xenobiotics had to evolve from assessing direct metabolic effects on
toxins and botanicals by conventional culture-based techniques to elucidating the role of community composition
on drugs metabolic profiles through DNA sequence-based phylogeny and metagenomics. Following the
completion of the Human Genome Project, the rapid, substantial growth of the Human Microbiome Project (HMP)
opens new horizons for studying how microbiome compositional and functional variations affect drug action, fate,
and toxicity (pharmacomicrobiomics), notably in the human gut. The HMP continues to characterize the microbial
communities associated with the human gut, determine whether there is a common gut microbiome profile
shared among healthy humans, and investigate the effect of its alterations on health. Here, we offer a glimpse into
the known effects of the gut microbiota on xenobiotic metabolism, with emphasis on cases where microbiome
variations lead to different therapeutic outcomes. We discuss a few examples representing how the microbiome
interacts with human metabolic enzymes in the liver and intestine. In addition, we attempt to envisage a roadmap
for the future implications of the HMP on therapeutics and personalized medicine.
Keywords: Human microbiome project, Xenobitoics, Liver enzymes, Metagenome, Microbiota, Metabolomics,
Metabonomics, Pharmacokinetics, Pharmacodynamics, PharmacomicrobiomicsIntroduction
The gut microbiota is the most predominant and most
diverse microbial community residing in the human
body [1]. It comprises hundreds of microbial species, to-
gether constituting about 10 times the number of body
cells [2,3], and contributes substantially to human meta-
bolic processes to the extent that up to 36 % of small
molecules in human blood are contributed by the gut
microbiome [4]. The gut microbiota’s impact on drug
response and metabolism has been explored since the
mid 20th century (reviewed in [5]); however, past studies
have mostly focused on assessing the metabolic activity* Correspondence: ramy.aziz@salmonella.org
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reproduction in any medium, provided the orof gut microbial communities on antibiotics and botani-
cals [6-9]. Meanwhile, the influence of the host genetic
makeup on drug response occupied the center stage of
personalized medicine research, specifically in the clin-
ical domain, leading to the rise of pharmacogenomic
approaches to personalized therapy, while a pivotal
player in xenobiotic metabolism, the microbiota, was
mostly being overlooked [10,11].
The various metabolic capabilities of the gut micro-
biota fueled the study of its effects on drug metabolism
[11,12]. Several approaches were adopted, including
comparisons between metabolic patterns of conventional
and germfree mice, biochemical assays of microbial
metabolic activities in cultures, and mutagenicity tests
[5,6,13]. Population-based approaches, such as investi-
gating the correlation between compositional variations
in gut microbiota and response to a particular drug, e.g.,
digoxin, were followed as well [9].d. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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based (i.e., sequencing genomes of bacterial species
after isolating their colonies) to culture-independent strat-
egies (metagenomics—or shotgun sequencing of microbial
and viral communities [14,15]) has allowed the identifica-
tion of the molecular signature of the gut microbiome
associated with a certain disease or with altered drug re-
sponse [16]. To describe this new expansion of pharmaco-
genomics, we suggested the term pharmacomicrobiomics
to denote the effect of microbiome variations on drug dis-
position and response [17,18]; here, we apply this concept
explicitly to the human gut microbiome, the best-studied
microbiome for its effect on xenobiotics.
In a broad sense, the term gut pharmacomicrobiomics
encompasses the effect of the gut microbiome variations
on pharmacokinetic and pharmacodynamic processes
[17,19] (See Section “Term disambiguation”). However, to
date, the better-documented effects of the human gut
metagenome on drugs are those related to metabolism
(i.e., effects on pharmacokinetic), either through: (i) the se-
cretion of enzymes that modify the chemical structure of
drug molecules, (ii) the secretion of metabolic products
that interfere with drug metabolism, (iii) the modification
of the levels and activities of liver and intestinal enzymes,
or (iv) the modulation of expression of human metabolic
genes [16] (Figure 1). Taking into consideration the enor-
mous number of gut-associated microbes, and the ex-
tremely large number of diverse genes they encode and
pathways they express, understanding the effect of the gutFigure 1 Different ways of interactions between the gut microbiome
and liver enzymes. Liver and intestine cartoons were taken from the pub
http://www.biochem.wisc.edu/medialab/clipart.aspx.microbiota on human response to drugs is an indispens-
able step towards providing a comprehensively tailored/
personalized therapy that would be more efficient, cost-
effective, and with lower adverse drug events [17,20].
In this review, we aim at providing an overview of the
influence of gut microbiota on drugs, spanning the
documented metabolic effects of the microbiota and the
different approaches used for their investigation. In
addition, we provide an outlook for the future of phar-
macomicrobiomics in the context of the Human Micro-
biome Project (HMP) and for the application of
metagenomic approaches as an integral part of pharma-
cotherapy and personalized medicine.
Term disambiguation
 Microbiome and microbiomics: To the best of our
knowledge, the term ‘microbiome’ was first
suggested in 2000 by the Nobel Laureate, Joshua
Lederberg, to describe the sum of microbial
genomes associated with the human body, which he
described as a part of “the human extended genome”
(URL: http://www.project-syndicate.org/
commentary/microbiology-s-world-wide-web). Soon
after, it was used in the same meaning in literature
[21,22]. Currently, however, microbiome is being
used to denote two different concepts: (i) the
collective microbial genome of a community (i.e.,
microbial metagenome) or (ii) the sum of alland drugs, sometimes involving dietary compounds or intestinal
licly available clipart of the University of Wisconsin, Madison. URL:
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environment (i.e., micro.biome). Microbiome was
initially confined to host-associated metagenomes,
but is now being used interchangeably with
microbial metagenome (e.g., the Earth Microbiome
Project http://www.earthmicrobiome.org/ [23]). The
less frequently used term, ‘microbiomics’, describes
the study of functional aspects related to the
microbiome, including the integration of high-
throughput genome-wide data [24].
 Pharmacogenomics and pharmacomicrobiomics:
Pharmacogenomics [25] is a well-established term
that describes the effect of human genome
variations on drug disposition and action. The term
can certainly be applied not just to the human
nuclear and mitochondrial genomes, but also to the
human extended genome or the genome of the
human supraorganism [18]; yet, to specify the
impact of the human-associated microbiome on
drugs, we have coined the term
pharmacomicrobiomics [17,18], which we consider
as a natural expansion of pharmacogenomics, which
is likely to spread when more HMP data accrue.
 Metabolomics and metabonomics: Those two
verbally similar terms have been sometimes used
interchangeably to describe the high-throughput
study of all genome-encoded metabolites produced
by a particular organism or a community; however,
Nicholson and coworkers carefully denote the
difference between the two terms as they use
metabolomics to describe the study of genetically
controlled metabolites and fluxes produced by one
type of cells or tissues, whereas they define
metabonomics as the measurement of metabolites
produced by a collection of cells/genomes within a
multicellular organism or an ecosystem [26] (the
latter once described as the ‘meta-metabolome’ [27]).
Role of gut microbiota in xenobiotic metabolism
The influence of the gut microbiota on the metabolism
of xenobiotics has been regarded extensively as a
response-modifying process, and several mechanisms
have been proposed and demonstrated [11]. Gut-
associated microbes can alter drug metabolism directly
by producing enzymes that degrade or activate the drug
molecules, or by competing with drug molecules over
the metabolizing enzymes [17,20]. In addition, the gut
microbiota may exert its influence by modulating the
activity or altering the levels of the host’s drug-
metabolizing enzymes or by producing enzyme-
inducing metabolites that are originally derived from
diet [28,29] (Figure 1). Accordingly, the microbiome’s
response-modifying effect has been widely appreciated
in nutrition and toxicology, and the role of gutmicrobiota in metabolism has initially been investi-
gated in terms of the metabolism of compounds of
dietary and botanical origin (Table 1).
Additionally, the absence of conventional gut micro-
biota in germfree mice has been correlated with pertur-
bations in levels of liver and intestinal metabolic
enzymes in comparison to their corresponding levels in
mice with conventional gut ecosystem [29], and conven-
tional gut microbiotas in human and mice were shown
to be associated with a modest elevation in the levels of
drug-metabolizing enzymes, such as sulfotransferase1 B1
(SULT1B1) and with reduced levels of other enzymes,
such as SULT1C1, NAT1 and NAT2 [28] (Table 2).
Impact of microbiome variations on drug response and
toxicity
Most studies on drug-microbe interactions did not take
in consideration the microbiome profile/composition of
an individual or a population; however, these variations
are the basis of pharmacomicrobiomics, and their study
has become possible now that the HMP has been estab-
lished [3,41], and HMP data have already been made
available [1,42].
Several studies associated a particular 16S rRNA mi-
crobial signature with specific biomarker metabolites
and clinical outcomes. This association has been
extended to encompass several conventional drugs such
as digoxin and acetaminophen [9,43]. Profiling the signa-
tures of the microbial communities in relation to their
metabolic effect on drugs among patients is likely to
introduce clinical markers that will dictate treatment
regimens tailored in accordance with each patient's resi-
dent microbiota [43]. Such regimens, in turn, will modify
the current treatment strategies that are based on con-
ventional pathologic and pharmacokinetic parameters to
take into account the interindividual perturbations in
the gut microbiota and the gut ecosystem. These mea-
sures are especially true with the evidence of the sym-
xenobiotic metabolism that involves both the host and
the associated microbiota to biotransform drugs, includ-
ing first-line therapies [9,44] (Table 3). As a conse-
quence, microbiome-labile medications may be limited,
or their dose readjusted, for certain populations or indi-
viduals harboring particular gut microbial community
profiles. Several drugs that possess structural similarity
to microbial products and are thereby potential candi-
dates of microbial metabolism are yet to be studied.
A systems biology view of the host-microbiota
metabolome and co-metabolome
Previously reported drug-microbe and drug-microbiome
interactions have mostly been described as phenotypic
observations of drugs being modified by a microbial spe-
cies, an entire microbial community, or an even more
Table 1 Role of gut microbiota in the metabolism of dietary compounds and phytochemicals











Carcinogenic agents HAAs, originally derived from
cooking proteins, are pro-mutagenic
compounds known to be
carcinogenic to rats and mice
reviewed in [30]. Normally upon
ingestion of a cooked protein,
gut microbiota metabolize these
compounds to yield unconjugated
mutagen metabolites detectable in
urine and stool, and human liver
enzymes CYP450 IA1 and IA2
activate these compounds to







The effect of elevated active
mutagens metabolites was reported
to be significantly higher in
conventional rats than germfree rats.
Conventional rats have shown
elevated activity of ethoxyresorufin-
O-deethylase (EROD), which is a
CYP450-dependent enzyme
responsible for the biotransformation
of HAAs and is increased in the small
intestine upon ingestion of fried
meat. Thus, the intestinal microbiota
is thought to play a central role in
HAA metabolism and thereby, in the
response to mutagens through
enhancing the activity of CYP450
enzymes responsible for the
activation of mutagens.
Cycasin {5459896} Toxic glycoside Members of the gut microbiota







Rutin {5280805} A quercetin glucoside
with angio-protective
effects
Several gut anaerobes, e.g.,
Bacteriodes uniformans, Bacteroides
ovatus, and Butrivibrio sp. hydrolyze
dietary rutin into its corresponding
quercetin aglycone and polyphenols.
The release of both the free
quercetin aglycone and the phenolic
metabolites underlies rutin’s
mutagenic effect and the further
inhibition of platelet aggregation,
respectively. The free quercetin
aglycone is a mutagen. Furthermore,
the administration of rutin has been
correlated with the increase of
mutagenic activity of other
glycosides with mutagenic aglycone
component. The increase in
glycosidic activity was expected to
further increase the release of
quercetin; however, the activation of
quercetin was decreased in rats fed
with rutin in contrast to the free
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Table 1 Role of gut microbiota in the metabolism of dietary compounds and phytochemicals (Continued)
Aflatoxin B1 {186907} Carcinogenic
mycotoxins
Rats with conventional gut
microbiota have shown two-fold
increase in aflatoxin concentration
in S9 liver fraction. Additionally, an
in vivo-modified Ames test showed
that rats with conventional gut
microbiota have higher number of
mutants of the indicator organism,
Salmonella Typhimurium TA98,
than germfree rats.




Anti-oxidants The effects of (+)-catechins and
(−)-epicatechins on liver and
intestinal enzymes have been
reported to be different between
germfree rats and rats with human
gut microbiota. In germfree rats,
(+)-catechins and (−)-epicatechins
resulted in increase in the levels of
liver CYP450 2C11 and (+)- catechins
caused elevation in the specific
activity of liver Uridine 5'-diphospho-
glucuronosyltransferase UGT-
chloramphenicol. On the other hand,
cytosolic glutathion-S-transferase
(GST) levels were higher in rats
harboring human gut microbiota
upon the administration of
(+)-catechins. However, in both
germfree and human microbiota
inoculated rats, (+)-catechins and
(−)-epicatechins increased the
specific activity of UGT-4-methyl
umbelliferone in the intestine.
Furthermore, the specific activity of
intestinal UGT-chloramphenicol was
higher in rats inoculated with
human microbiota.
Indirect potentiating/lowering
effect on drug metabolism
depending on the type of
co-administered drug, the
metabolic pathway adapted,
and the effect of the resulting
metabolite
[32]
2-methoxy esterone Anti-angiogenic Members of the gut microbiota are
believed to convert 2-methoxy
esterone to the active steroid form.
This was demonstrated upon
incubation of 2-methoxy esterone
with isolated rat cecum, where two
different reactions were found to
take place: oxidoreduction at C17
and demethylation at C2 resulting
into the active form.
Oxidoreduction and
demethylation resulting
in activation of prodrug
[33]




which are subjects to phase II
conjugation followed by excretion
in urine. In absence of gut
microbiota, chlorogenic acid is
metabolized to benzoic acid, which
in turn is conjugated with glycine
yielding hippuric acid. Gonthier et al.
found that the bioavailability of
chlorogenic acid relies on its
metabolism by gut microbiota [34].
Microbial metabolism resulting
in potentiated clinical effect
[34,35]
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Table 1 Role of gut microbiota in the metabolism of dietary compounds and phytochemicals (Continued)
Soy-derived phytoestrogens Xeno-estrogens Some microbial communities in the
gut produce active metabolites from
soy-derived phytoestrogens resulting
in enhanced efficacy. In addition,
the phytoestrogens metabolites
produced by gut microbiota are
suggested to affect cytochrome
P enzymes, which are responsible for
estrogen hydroxylation, and
therefore result in lower toxic events.
According to the type of
microbiota present, toxicity or
lower action may result.
[36,37]
Baicalin {64982} Potential antioxidant,
anti-inflammatory and
liver tonic
Gut microbiota normally hydrolyze
baicalin into its corresponding
aglycone baicalein, which is readily
absorbable and subject to
re-conjugation following absorption.
Absence of gut microbiota in
germfree rats reportedly resulted in
lower levels of baicalin in plasma
following oral administration.
Potentiated clinical effect [38]
Anthocyanins {145858} Potential anticancer,
anti-oxidant and
anti-inflammatory
Gut microbes are responsible for the
hydrolysis of the glycosidic linkage
between the sugar and the aglycone
by means of β-glucosidases resulting






Genistin {5281377} Anti-cancer, estrogenic
and antiatherosclerotic
Gut microbes hydrolyze the
glycosidic linkage between the sugar
and the aglycone by means of
β-glucosidases resulting in the






Naringin {442428 Anti-oxidant, anti-cancer
and blood cholesterol
lowering effect
Same as with anthocyanins and
genistin, microbial β-glucosidases
lead to the release of the free





CID = Chemical ID from the PubChem database (URL: http://pubchem.ncbi.nlm.nih.gov) [40] is provided in curly braces for all drugs or botanicals.
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component. However, in many cases the process, bio-
chemical pathway, or specific reaction remains un-
known, which renders the analysis of those interactions
by reductionist approaches difficult. Instead, exploring
the causality of those interactions might require systems
approaches such as the metagenomic analysis of the mi-
crobial community followed by the identification of dif-
ferentially abundant or differentially expressed candidate
genes or genomic subsystems [52] involved in those
interactions. Yet, metagenomic surveys that determine
microbial community profiles, gene presence/absence
and abundance, or functional classification of sequence
fragments are not sufficient to tell a coherent story
about the observed phenotypes since a gene’s presence
does not imply its expression or functionality. Conse-
quently, extracting knowledge from those microbiome
explorations and translating them into an ultimately tai-
lored therapy requires modeling the human microbiome,
variome, and interactions between them via integrating
multiple layers of information, including transcriptomic,
proteomic, and metabolomic data. Such integration is
not always achievable in a system with this complexity.For instance, a statistically sound correlation between
mRNA and protein expression levels in mid-log phase
Saccharomyces cerevisiae cells has been hindered by
technical limitations [53]. If this was the case with a uni-
cellular organism or with relatively uniform cell lines
[54], then further levels of complexity are to be expected
in the gut microbiome ecosystem, where communities of
unicellular organisms coexist in balance with the human
multicellular tissues. Systems biology approaches for
such complex communities are inevitable but are still in
early development [55,56].
From a holistic perspective, tailoring a pharmacother-
apy that accommodates intraindividual and interindivi-
dual variations would take into account the variations in
the host’s genetic makeup, its associated-microbiome,
and metabolomic interactions between the host and its
associated microbiota (i.e., co-metabolome). With the
recognition of the considerable role of the human
microbiome and its variations together with the formerly
well-recognized role of the human variome in predicting
response to pharmacotherapy, there is a growing de-
mand in both clinical and research domains for proper
computational models that are able to comprehensively
Table 2 Effect of microbiota on hepatic and intestinal metabolic enzymes [28]
Enzyme Function Effect of gut microbiome
Ethoxyresorufin-O-
deethylase (EROD)
A CYP450-dependent enzyme responsible
for the biotransformation of HAAs
The presence of normal gut microbiota in




Being among the alpha class of GST enzyme family
that is preferentially expressed in the colon rather
than the liver, it plays a central role in phase II
detoxification of xenobiotics. In addition, GSTA1/2
class displays a glutathione peroxidase activity,
which underlies its antioxidant and cyto-protective
effects.
Measuring GSTA1/2 levels in both germfree rats and
microbiota–reassociated rats showed 4- and 5-fold




Among the alpha class of GST enzymes that
possess high affinity to alk-2-enes
Germfree rats showed 1.5- and 1.9-fold increase in
the levels of GSTA4 than microbiota–reassociated
rats in males and females, respectively.
Glutathione S-transferase
M1 (GSTM1)
GSTM1 is one of the mu class of GSTs which
detoxify carcinogens, toxins, drugs and oxidative
stress products.
Germfree female rats showed a statistically
significant but modest elevation in colonic GSTM1
levels compared to rats with gut microbiota.
However, male rats didn't exhibit this elevation.
This increase in germfree female rats may be
coincidental in spite of the statistical significance.
Epoxide hydroxylase 1
(EPHX1) enzyme
Responsible for the activation and detoxification of
xenobiotics as polycyclic aromatic hydrocarbons
Germfree rats showed a substantial increase in the




Located in cell cytosol and perixosomes and
detoxifies specific peroxides by catalyzing their
conversion into dihydrodiols
Germfree rats showed a moderate increase in the




Among the SULT1 enzyme subfamily, which
conjugates phenolic compounds with sulfo groups
obtained from 3'-Phosphoadenosine-5'-
phosphosulfate (PAPS)
Germfree female rats showed a statistically




A member of the SULT1 enzyme subfamily On the contrary to SULT1C2, germfree male and
female rats showed a statistically significant decrease
(0.4- and 0.6-fold, respectively) in the enzyme level
than gut microbiota- associated rats.
N-acetyltransferase
1 (NAT1) & N-
acetyltransferase 2
(NAT2) enzyme
Detoxify hydrazine and arylamine drugs NAT enzyme levels were modestly elevated in




A selenium-dependent member of the GPX family
of glutathione peroxidase that is present in the
epithelium of the gastrointestinal tract
Elevated GPX2 mRNA levels have been correlated
with the reintroduction of microbiota in
germfree rats.
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best-recognized process in altered drug response, con-
trolled by both human genome and microbiome, is the
presystemic metabolism or first-pass effect (reviewed in
[57]). Since the metabolism of xenobiotics in humas is
performed by host and microbial enzymes, the meta-
bolic process is recognized as combinatorial or “sym-
xenobiotic” as recently described [10]. Furthermore, a
continuous metabolic interaction, termed metabolome-
metabolome interaction, exists between the host and
its associated microbiota [10]. Modeling the human/
microbiome variations and metabolome-metabolome
interactions will provide insights into the metabolism of
xenobiotics and thereby allow for accurate predictions for
drug response [26].
Nicholson and colleagues [26] attempted to visualize
the role of both the host and its associated microbiota inxenobiotic metabolism in the gut by proposing an inter-
esting model, assuming six different cell types in both
host and microbiota, every type of which has its own
transcriptome and metabolome depending on its role.
There is a mutual metabolic exchange between the host
and microbiota, and the extracellular compartment con-
tains metabolites generated by both of them. Those
metabolites are the result of drug and food metabolism,
and might lead to metabolic alterations in both the
host and its associated microbiota. This probabilistic
model of metabolism was introduced in an attempt to
tackle the potential interaction between the different
host- and microbiome-related factors that would
eventually display a certain outcome for metabolism.
The model likens the complex process of drug metab-
olism to a Japanese Pachinko (pinball machine), where
pins represent enzymes and transporters involved in
Table 3 Role of gut microbiota in the metabolism of conventional first line therapies and over-the-counter (OTC) drugs
Drug {CID} Pharmacological
effect
Role of gut microbiota in metabolism Effect of microbiota
on clinical outcome
References
Acetaminophen {1983} Analgesic and
antipyretic
Competitive o-sulfonation between
p-cresol, produced by some gut bacterial
communities, and acetaminophen
increases acetaminophen toxicity.
Therefore, assessment of microbiome
activity has been suggested as a guideline





Chloramphenicol {5959} Antibiotic Some patients display bone marrow
aplasia following the oral administration
of chloramphenicol owing to the presence
of coliforms that mediate the metabolic
conversion of chloramphenicol to a toxic
form known as p-aminophenyl-2-amin-1,2-
propanediol.
Increase toxicity [45]
Digoxin {2724385} Cardiotonic Altered concentration of Eggerthella lenta
between populations affects the
concentration of reduced digoxin
metabolite. 36 % of North Americans vs.
13.7 % southern Indians were able to
metabolize digoxin, a difference that was
correlated with altered concentrations of
E. lenta between the two populations.
Concomitant administration of digoxin and
erythromycin or tetracycline resulted in
digoxin intoxication. Accordingly, it is
recommended to avoid the concurrent




Flucytosine {3366} Antifungal Patients who have received antibiotics
showed lowered metabolic transformation
of flucytosine (commonly known as
5-fluorocytosine) to 5-fluorouracil (5-FU).
Potentiate effect [44]




Bacteroides fragilis is among gut
commensals, and its infection is commonly
treated by metronidazole. A strain of
B. fragilis that overexpresses recA was
resistant to metronidazole in comparison
to the wild-type strain. Inactivation of recA
resulted in the increased sensitivity to
metronidazole, and the B. fragilis recA
mutants had more double strand breaks.








Comparison of metronidazole metabolites
between germfree rats and conventional
rats showed the exclusive excretion of the
metabolites by conventional rats. Those
metabolites were retrieved upon adding
Clostridium perfringens to metronidazole.
Lower the effect by
activating metabolism
[13]
Sulfasalazine Azodyes/Antibiotics Salfasalazine is a prodrug that requires
activation by azoreduction, mediated by
intestinal bacteria, to result in sulfapyridine
and 5-aminosalisylic acid. Patients who
have undergone ileostomy had lower
plasma levels of sulfapyridine than controls.
Futhermore, antibiotic administration
resulted in decrease of the azoreduction
split. Intestinal microbiota mediate the
clearance of both sulfapyridine and
5-aminosalisylic acid, where the decrease
in acetylation rate is associated by
increased side effects.
Activate the drug [47]
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Table 3 Role of gut microbiota in the metabolism of conventional first line therapies and over-the-counter (OTC) drugs
(Continued)
Sulfinpyrazone {5342} Azodyes/Antibiotics The gut microbiota plays a major role in
the azoreduction of sulfinpyrazone.
Ilesotomy patients had dramatically lower
levels of the sulfide form than controls
(the area under the curve, AUC, for sulfide
metabolite was 25-fold lower in the
plasma in case of ileostomy patients).
Activate the drug [47]
Sulindac {1548887} Non steroidal
anti-inflammatory
drug (NSAID)
Sulindac is a prodrug that undergoes
reductive metabolism by gut microbiota
and liver enzymes into an active sulfone
metabolite. Patients with ileostomy
exhibited half the AUC following 12 hours
of oral administration of 200 mg dose.
Activate the drug [47,48]
Sorivudine {5282192} Antiviral A toxic interaction was reported in 18
Japanese people upon concomitant oral
administration of sorivudine and 5-FU.
Bacteroides sp. are responsible for this
toxicity owing to their production to
(E)-5-(2-bromovinyl) uracil (BVU) metabolite
which in turn deactivates
dihydropyrimidine dehydrogenase (DPD)
responsible for the metabolism of 5-FU.
Germfree rats had significantly lower BVU
levels in both urine and blood.
Increase toxicity [49,50]
Zonisamide {5734} Anticonvulsant Gut microbiota is central to the
metabolism of zonisamide by reduction
producing 2-sulfomoyacetylphenol.
Germfree rats had lower levels of this
metabolite, and its levels were increased
after those rats were inoculated with
gut microbiota.
Lower the effect [51]
CID = Chemical ID from the PubChem database (URL: http://pubchem.ncbi.nlm.nih.gov) [40] is provided in curly braces for all drugs.
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pathways are represented by the sequence of pins.
According to this model, the final outcome is the incre-
ment of the probabilities of collisions between pins and
balls [26].
Web resources for exploring gut pharmacomicrobiomics
 Human variome resources: HVP (Human Variome Project): http://www.
humanvariomeproject.org [58]
 HapMap: http://hapmap.ncbi.nlm.nih.gov [59]
 Human microbiome resources:
 MetaHIT (Metagenomics of the Human
Intestinal Tract): http://www.metahit.eu [42]
 HMP: http://hmpdacc.org [41]
 Tools or databases for browsing the human
microbiome:
 IMG/HMP: http://www.hmpdacc-resources.org/
cgi-bin/imgm_hmp/main.cgi [41] myMGDB: http://edwards.sdsu.edu/cgi-bin/
mymgdb/show.cgi
 MG-RAST: http://metagenomics.anl.gov [60]




 PharmGKB (Pharmacogenomics Knowledge
Base): http://www.pharmgkb.org [62]
 PacDB (Pharmacogenetics and Cell Database):
http://www.pacdb.org [63]
 CTDB (Comparative Toxigenomics Database):
http://ctdbase.org [64]
 The PharmacoMicrobiomics Portal: http://www.
pharmacomicrobiomics.org [65]
 Enzymes/pathways databases:
 KEGG (Kyoto Encyclopedia of Genes and
Genomes): http://www.genome.jp/kegg/ [66]
 Model SEED: http://seed-viewer.theseed.org/
seedviewer.cgi?page=ModelView [67]
 BRENDA (BRaunschweig ENzyme Database):
http://www.brenda-enzymes.org [68]
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The current advances in the Human Variome Project
[69,70] and the HMP [3,41], together with a battery of
publicly available web resources (See Section “Web
resources for exploring gut pharmacomicrobiomics”)
offer a starting point for those interested in drug-
microbiome interactions to address several intriguing
questions. However, the examples reported previously
(e.g., those in Tables 1, 2 and 3) are just the tip of an ice-
berg of yet-to-be-discovered interactions between the
host variome, associated microbiome, their combined
metabolome, and chemicals ingested by humans. Ultim-
ately, the study of those interactions in spite of their
complexity is driven by the need for devising persona-
lized therapeutic regimens aiming at optimizing drug
bioavailability to obtain maximal efficiency and minimal
toxicity. Below, we suggest a roadmap of four steps for
the development of the nascent field of gut pharmacomi-
crobiomics and its translation into personalized medicine
(Figure 2).
Capturing current knowledge
The first step is to capture and organize the currently
available information on drug-microbiome complex
interactions by building databases similar to those built
for pharmacogenetics, pharmacogenomics, and drug-
drug interactions. Concomitant with building databases
is developing tools and resources to support discovery
by mining those databases and connecting them toFigure 2 A roadmap for the development of the nascent field of gut
domain.microbial genomic databases (e.g., SEED [61], GOLD
[71]) metagenomic/microbiome databases, (e.g., MG-
RAST [60], myMGDB, HMP [41], METAHIT [42]), and
metabolic pathway databases (e.g., KEGG [66], model-
SEED [67], BRENDA [68]).
Developing and performing high-throughput screens for
novel drug-microbiome interactions
In parallel with capturing existing knowledge, there is
continuous need for digging deeper into the unknown
drug-microbiome interaction space. Addressing this
need can be achieved via studies involving high-
throughput screens of drugs against human microbiota
from different individuals looking at the overall action of
these microbiotas on representatives of different drug
classes, or, reciprocally, via screening individual resident
gut microbes against large libraries of drugs or other
chemicals.
Developing software and building models for drug response
simulation
The accumulated data in literature pointing out to the
response variation mediated by mammalian host var-
iome and microbiome calls for the construction of mod-
eling software that considers all such parameters to
provide rational hypotheses or accurate predictions for
research [26,55,72]. Developing such modeling software
and using it in building models requires encoding data
compiled from the literature regarding the host variome,pharmacomicrobiomics and its translation into the clinical
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these encoded data into a model capable of retrieving an
informative index describing the predicted outcome. For
instance, Hlavaty and colleagues [73] used a similar ap-
proach to construct a predictive model of an apoptotic
pharmacogenetic index for infliximab in treatment of
Crohn disease. Following data mining, they used SASW
enterprise miner software to analyze all the genetic var-
iants involved with the apoptotic response of infliximab,
they managed to develop a new pharmacogenetic index
ranging from 0 which denotes diminished response to 3,
indicating a powerful response [73].Data integration and translation into the clinical domain
The availability of web resources, the generation of more
data, and the construction of rigorous models for drug-
microbiome interactions will offer a great opportunity to
translate this knowledge into diagnostic and clinical
measures. In the future, routing clinical practices should
include integrating microbiome data and processing
them to produce valid assumptions of clinical outcome,
based on which the type, dose, and regimen of treatment
will be planned for each patient. Accordingly, each case
will have its own panel of personalized therapy. For in-
stance, patients harboring gut microbiota known to be
associated with elevated levels of metabolic enzymes will
be scheduled for higher doses; patients with higher sus-
ceptibility to acetaminophen toxicity might either be
given a lower dose or an alternative nonsteroidal anti-
inflammatory medicine; and patients with a microbiota
with higher ability to metabolize digoxin will be sched-
uled to receive lower dose.Conclusions
Throughout the past five decades, the study of the effect
of gut microbiota went through several phases uncover-
ing its ample significance in drug response. With the
continuous growth of the HMP and its expansion to
cover diverse human populations, it is anticipated that
the primary data concerning the common gut micro-
biome profile and its diversity among humans will be
revealed, enabling to pursue further studies on its effect
on drug response among populations. However, several
steps are yet to be taken in anticipation of the floods of
HMP data, including the construction of databases, soft-
ware, and models that would provide credible predic-
tions of differential clinical outcome and fuel further
hypothesis-driven studies whose findings might be inte-
grated into clinical settings.Competing interests
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